| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.11 | 0.4 |